RUBINSTEIN JULIE sold $897K of ADPT
RUBINSTEIN JULIE (President and COO) sold 35,643 shares of Adaptive Biotechnologies Corp (ADPT) at an average of $25.18 ($24.21–$25.82, $0.90M total) across 5 trades over 2026-10-14 to 2026-10-16 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosed sale may cause short‑term price softness, especially if investors interpret it as a lack of confidence.
Market read
Insider sales are closely watched; this filing adds a data point for ADPT's ownership structure.
What to watch
The insider retains a sizable stake, and the sale price was near recent trading levels, suggesting no panic.
Background
Form 4 filings provide the first public disclosure of insider transactions, offering transparency on executive holdings.
Ticker impact
President and COO Julie Rubinstein sold 35,643 shares for $897K via a 10b5‑1 plan, reducing her stake to 377,802 shares.
likely modest downward pressure as the market prices the insider sell
A $0.9M sale by a senior executive is material for a mid‑cap biotech, but the amount is modest relative to market cap, so impact is limited.
Market effects
May prompt scrutiny of insider activity in the biotech sector, but no broader sector shift.
Limited to U.S. biotech investors; no regional effect.
Minimal global impact.
Counterpoint
The sale could be routine under a pre‑arranged plan and not reflect negative outlook.
Key entities
- ExecutiveJulie Rubinstein
President and COO of Adaptive Biotechnologies, reporting the sale.
- CompanyAdaptive Biotechnologies Corp
Biotech firm developing immune profiling technologies.
